Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
View original at finance.yahoo.comJazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer For U.S…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Zepzelca is an important treatment in SCLC and, based on the strength of the IMforte trial results, its most beneficial use is in the first-line maintenance setting in combination with immunotherapy given the rapid progression of metastatic SCLC after first-line chemotherapy induction.
60% confidenceThe LAGOON trial included a broader patient population than the Phase 2 pivotal trial that supported the second-line accelerated approval, including patients with a history of CNS involvement.
60% confidenceNo new safety signals were identified with Zepzelca monotherapy or in combination with irinotecan in the LAGOON trial, and the overall safety profiles were consistent with the known safety profile of each agent.
60% confidenceRelapsed SCLC is an aggressive cancer with a poor prognosis and patients continue to need treatment options, including in later lines of therapy.
60% confidenceIn the IMforte trial, the Zepzelca and atezolizumab combination reduced the risk of disease progression or death by 46% and the risk of death by 27% compared to atezolizumab maintenance therapy alone.
60% confidenceThe LAGOON study results do not impact the company's 2026 guidance.
60% confidenceEfficacy of Zepzelca in the subset of patients without a history of CNS involvement was more comparable to the control arm, which performed better than historical precedent.
60% confidenceThe LAGOON results are distinct from the IMforte trial and do not impact Zepzelca's approval in the first-line maintenance setting.
60% confidence